Clinical Trial Update: Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of thalidomide and epoetin alfa for treating anemia in patients with myelodysplastic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Epogen (epoetin alfa)
• PROCRIT (ERYTHROPOIETIN)
• Thalidomide (thalidomide)
• Thalomid (thalidomide)

Snippet

Sponsor: Fallon Clinic | Conditions: Anemia, Leukemia | Phase 2 | Status: COMPLETED